In 2023, the mortality rate from Cervix Uteri Malignant Neoplasms in the US was recorded at around 4.29 thousand female deaths. From 2024 to 2028, it is projected to increase gradually from 4.31 to 4.39 thousand deaths. This demonstrates a year-on-year variation of approximately 0.46% per annum over the forecast period. The average annual growth rate (CAGR) over the five-year horizon (2024-2028) is estimated at about 0.46%.
Future trends to watch include advancements in cervical cancer screening and vaccination programs, which may mitigate mortality rates. Additionally, enhanced access to healthcare services and tailored interventions for high-risk populations could influence future projections positively.
